Key result
AGTR1 A1166C genotype linked to ~242% greater cardiovascular disease risk in an admixed Mexican population.
Why the study?
The relevance of the AGTR1 rs5186 polymorphism to cardiovascular disease risk in genetically admixed populations, such as Mexicans, remains unclear.
Case-Control (n=356)
Odds Ratio: 3.42 (95% CI 1.16–10.08)
p-value: p=0.04
The AGTR1 rs5186 polymorphism (A1166C genotype) and elevated levels of serum amyloid A and homocysteine are independently associated with increased cardiovascular disease risk in an admixed Mexican population.
The angiotensin II type 1 receptor ( AGTR1 ) rs5186 (A1166C) polymorphism has been associated with cardiovascular disease (CVD) risk. However, its relevance in genetically admixed populations, such as Mexicans, remains unclear. The aim of this study was to evaluate the association between the AGTR1 rs5186 polymorphism and CVD risk in a Mexican population, while integrating key inflammatory and metabolic biomarkers. A case-control study was conducted with 356 participants from Nayarit, Mexico, classified into three groups: CVD (n = 118), hypertension free of CVD (HTN, n = 119), and healthy controls (n = 119). Genotyping of rs5186 was performed via real-time PCR. Logistic regression models were adjusted for sociodemographic, clinical, and lifestyle variables, including serum amyloid A (SAA) and homocysteine levels. The A1166C genotype was independently associated with CVD risk (OR = 3.42, 95% CI: 1.16, 10.08). Elevated SAA (OR = 1.01, 95% CI: 1.01, 1.02) and homocysteine (OR = 3.20, 95% CI: 1.93, 5.33) were also significant predictors. These associations persisted after adjusting for potential confounders. This study highlights the relevance of AGTR1 rs5186 and inflammatory biomarkers in CVD susceptibility in a Mexican admixed population. Findings support the inclusion of genetic screening and inflammatory profiling in population-specific preventive strategies.
No takes yet. Share an insight, caveat, or question.
Herrera-Moreno et al. (2026) conducted a case-control in Cardiovascular disease (n=356). AGTR1 rs5186 (A1166C) polymorphism vs. Healthy controls / Non-carriers was evaluated on Cardiovascular disease risk (OR 3.42, 95% CI 1.16-10.08, p=0.04). The AGTR1 A1166C genotype was independently associated with a significantly increased risk of cardiovascular disease (OR 3.42) in an admixed Mexican population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: